cimetidine + CHF5993

Cimetidine is a small molecule drug classified as a histamine H2 receptor antagonist (H2 blocker) that reduces stomach acid production. It is primarily used to treat gastric and duodenal ulcers, gastroesophageal reflux disease (GERD), erosive esophagitis, and conditions of excessive gastric acid secretion such as Zollinger-Ellison syndrome. Cimetidine works by competitively inhibiting histamine at H2 receptors of the gastric parietal cells, thereby decreasing both the volume and acidity of gastric secretions[1][4][7][8]. CHF5993 is an inhaled fixed-dose combination therapy containing three active components: beclometasone dipropionate (an inhaled corticosteroid), formoterol fumarate (a long-acting beta2 agonist), and glycopyrronium bromide (a long-acting muscarinic antagonist). It is developed for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma. The combination aims to provide anti-inflammatory effects, bronchodilation via beta2 agonism, and antimuscarinic activity for improved airway function[5]. The co-administration of cimetidine with CHF5993 has been studied in healthy volunteers to assess pharmacokinetic interactions. Results indicate that while there are small increases in systemic exposure to some components when combined with cimetidine, these changes are not clinically significant; no relevant drug-drug interaction was observed[2][5].

Brand names

TagametTagamet HB

Other names

cimetidineCHF 5993CHF5993CHF-5993